1.5 mg retatrutide - GLP-1 / GIP / GCGR Tri-Agonist Retatrutide Dosage: 5 mg Vial

By May 2025, the dosage had been systematically increased to a maintenance level of 2.4 mg weekly

New Episode News and Public Affairs Today's top journalists discuss Washington's current political events and public affairs

If you typically inject in the morning and exercise later in the day, this may not matter much

10.1211/PJ.2025.1.359584 Pharm J

Although the enrichment of L-cells by pharmacological agents can be a novel approach for improving insulin secretion, glucose tolerance and the treatment of T2DM, more research for the specific differentiation of L-cells and the translation of in vitro and animal data to humans, are needed for the success of this approach